By Find Peptide Clinics. Each claim below is checked against the FDA prescribing information, cited at the end.
There is a sentence in the tirzepatide label that tells a woman her birth control pill may stop working. It is not buried in fine print. It appears in three separate sections of the prescribing information, in the same words each time.
Almost no one who starts this drug hears it.
That is the pattern worth understanding, because it repeats. The interactions that matter with tirzepatide are not exotic. They are ordinary things people already do, quietly affected by one mechanism the drug was built to produce. Once you can see the mechanism, you can work out the rest yourself, including the ones no list has ever mentioned to you.
The Whole Thing Runs on Three Changes
Tirzepatide does three things that have nothing to do with chemistry.
It slows how fast your stomach empties, a delay that is strongest right after the first dose and after each dose increase. It turns your appetite down. And it blunts thirst, quietly enough that people who are mildly dehydrated will tell you they drink plenty of water.
Hold those three together and most of what follows stops being mysterious. The drug is not reacting with your other medicines. It is changing the conditions those medicines were counting on: how fast something gets absorbed, how much fluid you have onboard, how empty your stomach is when somebody assumes it is empty.
Birth Control: the One Printed on the Label
Start here, because this one is written down and still gets missed.
The Zepbound and Mounjaro prescribing information tells patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after each dose escalation. The label explains why: tirzepatide delays gastric emptying, and a pill needs to leave the stomach on a schedule to be absorbed on a schedule. Slow the stomach and the schedule stops being reliable.
The numbers behind it come from a drug interaction study cited in the label. A single 5 mg dose of tirzepatide reduced peak blood levels of ethinyl estradiol by about 59 percent, and of norgestimate by about 66 percent. Overall exposure fell by roughly 20 to 23 percent, and the time to peak was delayed by two and a half to four and a half hours. The peak matters most, because contraceptive failure is a question of whether the hormone level ever gets high enough.
The part most people get wrong is the second half. People remember the four weeks after the first dose. Almost no one remembers that the clock restarts at each increase. Since standard titration steps up about once a month, a patient following the label to the letter spends most of the titration in near-continuous backup mode.
Methods that do not pass through the stomach are unaffected. The label says so directly. An IUD, the implant, the injection, the patch and the ring are not subject to this interaction, which is why so many clinicians recommend switching rather than tracking overlapping four-week windows across five dose steps.
Stop the Drug the Moment You’re Pregnant. The Label Says So. Nobody Told You.
Read the sentence in the FDA’s own record, then notice how rarely it is quoted anywhere else.
Pregnancy: May cause fetal harm. The label adds that weight loss offers no benefit to a pregnant patient, and it instructs patients to discontinue ZEPBOUND when a pregnancy is recognized.
That is not a caution about planning. It is an instruction to stop the medication the moment you find out you are pregnant. Which is why the contraceptive warning above is not a footnote. It is the part of this label carrying the highest stakes, and it is the part patients most often hear secondhand.
Surgery and Sedation: Straight From the Label
This one is also written down, and it is dangerous.
The GLP-1 labels describe rare postmarketing reports of pulmonary aspiration in patients having surgery or procedures under general anesthesia or deep sedation, who had residual stomach contents despite following the standard fasting instructions. The delay in gastric emptying means an empty stomach by the clock is not the same as an empty stomach in fact. The labels state there is not enough data to say whether changing fasting rules or stopping the drug beforehand reduces the risk.
The practical consequence is simple: tell whoever is sedating you that you are on this medication. That is the instruction the label itself gives.
Insulin and Sulfonylureas: the One That Pushes the Same Way
The semaglutide label states plainly that the risk of hypoglycemia increases when the drug is used with insulin or with an insulin secretagogue such as a sulfonylurea, and that the dose of those may need reducing.
Read the mechanism rather than the warning. Tirzepatide lowers blood sugar. Insulin lowers blood sugar. Nothing reacts with anything. You have aimed two forces at the same wall, and the wall is your blood glucose.
Levothyroxine: a Real Measured Interaction, Not With This Drug
Worth knowing because people confuse the class. In an oral semaglutide drug interaction study, levothyroxine exposure rose 33 percent when the two were taken together, which is why that label tells patients to separate the doses. That is a measured interaction with oral semaglutide specifically, not a tirzepatide finding, and anyone on thyroid medication should be asking about timing regardless.
The Ones Not on the Label, and Why They Still Matter
Here is where honest information departs from a listicle. A great many things get described online as drug interactions with tirzepatide. The label does not list most of them. That does not make them irrelevant. It means the reason they matter is different, and you should know which category you are in.
Anti-inflammatory painkillers during a bad stomach day. Ibuprofen, naproxen and similar drugs are not listed as a tirzepatide interaction. The concern is a situation, not a combination: vomiting or diarrhea plus blunted thirst can reduce blood volume, and reduced blood flow is what kidneys are vulnerable to. Anti-inflammatories blunt the compensatory mechanism kidneys rely on in exactly that state. Take away fluid, take away blood flow, switch off the backup, and you have the setup for an acute kidney injury over a bad weekend. The trigger is dehydration, and it matters more if you also take a diuretic or a blood pressure medicine ending in -pril or -sartan.
Insulin and blood sugar medicines. Covered above, and the label names them.
Fasting and severe calorie restriction. Not an interaction. An amplifier. Eat far less while your stomach is already emptying slowly and you add to the nausea and the dizziness.
Fiber supplements and constipation. Fiber is fine. Fiber without enough water is the problem, and the drug has already turned your thirst signal down.
Stimulant fat burners and pre-workouts. Not labeled. Worth caution because stimulants raise heart rate and blood pressure while your fluid balance is already compromised, and because the supplement market is unregulated.
Alcohol. Not labeled as an interaction. It lowers blood sugar, it dehydrates, and it irritates the stomach, which is three of the drug’s own effects in one evening. That is the reason for caution, and it is reason enough.
Drug interaction checkers. Useful, and unreliable in one specific way. An app that flags nothing is not reassurance, because absence of a flagged interaction and absence of any information look identical on a screen. Proprietary blend supplements are the clearest example: there is no finding because there is nothing to study.
Three Questions That Work on Everything
You do not need the list. You need the test, and it takes about ten seconds per item.
One: does this need to be absorbed on a schedule to work? If yes, a slower stomach may be a problem for it. That covers oral contraceptives, and it is worth asking about anything else where timing is the point.
Two: does this push in the same direction the drug is already pushing? Lower blood sugar, less fluid, more stomach irritation. If it does, you are not adding a treatment, you are doubling a pressure. Insulin, alcohol and fiber without water all live here.
Three: if something is flagged, how is it flagged, and is anything behind it? Not being on a list means no finding exists. It does not mean nothing is there. The middle tier means a tool noticed two things in the same room and wants a human to look. That is a question for your prescriber, not a reason to stop anything on your own.
The Question This Raises
Each item above comes back to the same thing: somebody should have explained it to you. Not because the information is secret, but because it is written in a document no one hands you when you buy the drug.
A state-licensed compounding pharmacy under Section 503A operates with a pharmacist who is supposed to be part of that conversation, who can see your other prescriptions, and who has an obligation that outlives the transaction. That is not a marketing claim, it is the licence.
That is exactly the difference between buying from a licensed pharmacy and buying from a chat window. We spent three weeks documenting what a peptide sales operation looks like when it hides on a town website. It does not have a pharmacist. It does not have a licence. It does not have anyone who will ever ask what else you take.
The interaction advice above is not sophisticated. It is the standard of care that a real pharmacy already owes you, and the fact that a 22-minute video explaining it has been watched a quarter of a million times tells you how many people were handed a prescription and told nothing.
Which of these compounds may a compounding pharmacy lawfully prepare, and in which state? The peptide regulatory status tracker sets out FDA status compound by compound, with dates and sources.
Frequently Asked Questions
Does tirzepatide make birth control pills less effective?
Yes, and unlike the other GLP-1 medications this is stated directly in the prescribing information. Women using oral hormonal contraceptives should switch to a non-oral method or add a barrier method for four weeks after starting, and for four weeks after each dose increase.
Do other GLP-1 medications carry the same contraceptive warning?
No. The labeled oral contraceptive warning is specific to tirzepatide, the dual GIP and GLP-1 agonist sold as Mounjaro and Zepbound. The semaglutide labels do not carry it.
Should I stop my tirzepatide before surgery?
Do not change anything on your own. The instruction in the label is to tell your healthcare providers you are taking it before any planned surgery or procedure, because delayed gastric emptying can leave stomach contents despite standard fasting.
Is it safe to compound tirzepatide?
Compounded tirzepatide is prepared by state-licensed pharmacies under Section 503A, and the FDA’s position on compounded versions of approved drugs has changed repeatedly during the recent shortage cycles. Whether a specific pharmacy may lawfully prepare it depends on current FDA guidance and your state’s rules, and it is worth confirming directly rather than assuming.
What should I ask a compounding pharmacy before I pay?
Ask for its state licence number and which state board issued it, ask the name of the pharmacist responsible, ask where it sources its bulk ingredient and whether it holds a certificate of analysis, and ask what happens if you need to talk to a pharmacist about your other prescriptions. A real pharmacy answers all four without hesitation.
Sources: ZEPBOUND (tirzepatide) US Prescribing Information §7.2, §8.3 and §17 (DailyMed); MOUNJARO (tirzepatide) US Prescribing Information §7.2 and §8.3; OZEMPIC (semaglutide) US Prescribing Information §7.2; RYBELSUS (semaglutide) US Prescribing Information §7.1 and §7.2; WEGOVY (semaglutide) Prescribing Information; FDA Center for Drug Evaluation and Research, Clinical Pharmacology Review, Mounjaro NDA 215866.